Advertisement
Canada markets open in 6 hours 59 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7311
    +0.0013 (+0.18%)
     

  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    87,983.60
    -3,190.16 (-3.50%)
     

  • CMC Crypto 200

    1,391.09
    +8.51 (+0.62%)
     

  • GOLD FUTURES

    2,330.40
    -8.00 (-0.34%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,430.50
    -234.00 (-1.32%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6813
    -0.0006 (-0.09%)
     

Five Star Equities Issues New Research Reports on EXAS, IDRA, LPDX and OXM

ACCESSWIRE

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

EXACT Sciences Corp. (NASDAQ:EXAS - News) shares declined 6.47 percent to close at $12.86 a share Friday. The stock traded between $12.52 and $14.60 on volume of 9.32 million shares traded. The company announced that an FDA Advisory Committee has unanimously voted to recommend Cologuard, a colorectal cancer screening test, for approval. Shares of EXACT Sciences are up approximately 10.0 percent year-to-date.

Get more information on EXACT Sciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/EXAS

Idera Pharmaceuticals Inc. (NASDAQ:IDRA - News) shares surged 17.78 percent to close at $4.57 a share Friday. The stock traded between $4.22 and $4.80 on volume 19.70 million shares traded. The company reported positive results from a recent Phase 2 trial that showed IMO-8400 met its primary objective. Shares of Idera Pharmaceuticals are down approximately 2.0 percent year-to-date.

ADVERTISEMENT

Get more information on Idera Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/IDRA

LipoScience Inc. (NASDAQ:LPDX - News) shares dropped 19.63 percent to close at $3.03 a share Friday. The stock traded between $2.97 and $3.63 on volume of 1.03 million shares traded. The company announced the terminations of its contract with Health Diagnostics Laboratory, Inc. Shares of LipoScience are down approximately 28.0 percent year-to-date.

Get more information on LipoScience and free access to the in-depth equity report at:
www.FiveStarEquities.com/LPDX

Oxford Industries, Inc. (NYSE:OXM - News) shares increased 3.22 percent to close at $76.28 a share Friday. The stock traded between $73.04 and $78.41 on volume 162,526 shares traded. The company reported net sales were $250.4 million for the fourth quarter of fiscal 2013, an increase of 6.0 percent when compared to a year ago. Shares of Oxford Industries are down approximately 5.0 percent year-to-date.

Get more information on Oxford Industries free access to the in-depth equity report at:
www.FiveStarEquities.com/OXM

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com